A reader named Karen e-mailed today, asking me to post information about a new German multiple myeloma research break-through.
One big step ahead of you, Karen! Here is the link to a post I made the day after the news was released in Early May.
The research Karen references is being conducted by a company named Boehringer Ingelheim, with the help of an American company, Micromet, Inc.
Here is a quote from Boehringer/Ingelheim’s Head of Corporate Research:
“We recognize the advantage of combining Micromet’s BiTE antibody platform with our target identification and development expertise and we believe that a BiTE antibody has the potential to address the significant unmet medical need of patients with multiple myeloma,” said Wolfgang Rettig, M.D., Ph.D., Head of Corporate Research, Boehringer Ingelheim. “This collaboration builds on the unique strengths of Micromet and Boehringer Ingelheim.”
Thanks, Karen. I will keep our readers updated on any progress this collaborative effort makes in the upcoming months.
Keep that anti-Myeloma research coming!
Feel good and keep smiling! Pat